Cytisine eye drops for benzalkonium chloride-induced dry eye : safety and efficacy evaluation
This experiment aimed to investigate the feasibility of cytisine (CYT) in treating eye diseases with ocular topical application. An in vitro cytotoxicity test, a hen's egg test-chorioallantoic membrane (HET-CAM), and a mouse eye tolerance test were used to fully reveal the ocular safety profiles of CYT. For the efficacy evaluations, CYT's effects on cell wound healing, against H2O2-induced oxidative stress damages on cells, and on benzalkonium chloride (BAC)-induced dry eye disease (DED) in mice were evaluated. Results showed that CYT did not show any cytotoxicities at concentrations no higher than 250 μg/ml, while lipoic acid (α-LA) at 250 μg/ml and BAC at 1.25 μg/ml showed significant cytotoxicities within 48 h incubation. The HET-CAM and mouse eye tolerance test confirmed that 0.5% CYT eye drops demonstrated good safety characteristics. Efficacy evaluations showed that CTY significantly promoted cell migration and wound healing. CYT significantly improved cell survival against H2O2-induced oxidative stress damage by reversing the imbalance between the reactive oxygen species (ROS) and antioxidant defense mechanisms. The animal evaluation of the BAC-induced dry eye model revealed that CYT demonstrated a strong treatment effect, including reversing ocular surface damages, recovering corneal sensitivity, and inhibiting neovascularization; HMGB1/NF-κB signaling was involved in this DED treatment by CTY. In conclusion, CYT had strong experimental treatment efficacy against DED with good ocular safety profiles, and it might be a novel and promising drug for DED.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Pharmaceutical development and technology - (2024) vom: 22. Apr., Seite 1-11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Zijian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytisine |
|---|
| Anmerkungen: |
Date Revised 22.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/10837450.2024.2345148 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371188369 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371188369 | ||
| 003 | DE-627 | ||
| 005 | 20240422232454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240417s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10837450.2024.2345148 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1383.xml |
| 035 | |a (DE-627)NLM371188369 | ||
| 035 | |a (NLM)38629738 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Zijian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytisine eye drops for benzalkonium chloride-induced dry eye |b safety and efficacy evaluation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a This experiment aimed to investigate the feasibility of cytisine (CYT) in treating eye diseases with ocular topical application. An in vitro cytotoxicity test, a hen's egg test-chorioallantoic membrane (HET-CAM), and a mouse eye tolerance test were used to fully reveal the ocular safety profiles of CYT. For the efficacy evaluations, CYT's effects on cell wound healing, against H2O2-induced oxidative stress damages on cells, and on benzalkonium chloride (BAC)-induced dry eye disease (DED) in mice were evaluated. Results showed that CYT did not show any cytotoxicities at concentrations no higher than 250 μg/ml, while lipoic acid (α-LA) at 250 μg/ml and BAC at 1.25 μg/ml showed significant cytotoxicities within 48 h incubation. The HET-CAM and mouse eye tolerance test confirmed that 0.5% CYT eye drops demonstrated good safety characteristics. Efficacy evaluations showed that CTY significantly promoted cell migration and wound healing. CYT significantly improved cell survival against H2O2-induced oxidative stress damage by reversing the imbalance between the reactive oxygen species (ROS) and antioxidant defense mechanisms. The animal evaluation of the BAC-induced dry eye model revealed that CYT demonstrated a strong treatment effect, including reversing ocular surface damages, recovering corneal sensitivity, and inhibiting neovascularization; HMGB1/NF-κB signaling was involved in this DED treatment by CTY. In conclusion, CYT had strong experimental treatment efficacy against DED with good ocular safety profiles, and it might be a novel and promising drug for DED | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cytisine | |
| 650 | 4 | |a cytotoxicity | |
| 650 | 4 | |a dry eye disease | |
| 650 | 4 | |a ocular tolerance | |
| 700 | 1 | |a Song, Xixi |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Yanjun |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Xianggen |e verfasserin |4 aut | |
| 700 | 1 | |a Jie, Ying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical development and technology |d 1998 |g (2024) vom: 22. Apr., Seite 1-11 |w (DE-627)NLM094740194 |x 1097-9867 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:22 |g month:04 |g pages:1-11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10837450.2024.2345148 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 22 |c 04 |h 1-11 | ||